Search clinical trials for: car transportation

Total 14973 results

Hangzhou Cheetah Cell Therapeutics Co., Ltd

Recruiting

NKG2D CAR-NK & Ovarian Cancer

Ovarian Cancer

China
OneChain Immunotherapeutics
Hospital Clinic of Barcelona; Hospital Sant Joan de Deu; BioClever 2005 S.L.

Recruiting

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL (CARxALL)

T-cell Acute Lymphoblastic Leukemia | Lymphoblastic T-Cell Lymphoma

Spain
Xuanwu Hospital, Beijing
Baoding Children's Hospital

Recruiting

CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia

T-cell Acute Lymphoblastic Leukemia

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Universal CAR-γδT Cell Injection in the AML Patients

AML

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions

Hematological Malignancies

China
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital

Not yet recruiting

Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia

Leukemia
Assistance Publique Hopitaux De Marseille

Completed

Effectivness of Distraction by Electric ride-on Cars for Peri Operative Anxiety in Ambulatory Pediatric Surgery (PTIBOLID)

Anxiety

France
Uppsala University
Uppsala University Hospital; AFA Insurance

Completed

CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy

B-Cell Lymphoma | B-cell Leukemia

Sweden
University Hospital, Antwerp

Terminated

Car Safety Seat and Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease and Position

Belgium
Shanghai Tong Ren Hospital
Gracell Biotechnology Ltd.

Unknown

CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies

B-cell Lymphoma | B-cell Malignancy | B-Cell Acute Lymphoblastic Leukaemia

China
Shenzhen Geno-Immune Medical Institute

Unknown

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Multiple Myeloma

China
First Affiliated Hospital of Zhejiang University

Unknown

B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma

Multiple Myeloma

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Medical University Fourth Hospital

Unknown

CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Lymphoma | Leukemia

China
Zhejiang University
Hangzhou Cheetah Cell Therapeutics Co., Ltd

Recruiting

NKG2D CAR-NK & r/rAML

AML

China
Shanghai Cell Therapy Group Co.,Ltd

Recruiting

Study of αPD1-MSLN-CAR T Cells to Evaluate the Safety, Tolerability, and Effectiveness for Patients With MSLN-positive Advanced Solid Tumors

Colorectal Cancer

China
The First Affiliated Hospital of Soochow University
The First Affiliated Hospital with Nanjing Medical University; The Affiliated... and other collaborators

Recruiting

Sequential Infusion of CD19 and BCMA CAR-T Cells to Improve PTR in Patients With AL

Platelet Transfusion Refractoriness | Acute Leukemia in Remission

China
Zhejiang University

Recruiting

CAR-T Cellular Therapy for B Cell Malignancies Involved in CNS

Hematological Malignancy

China
Guangzhou 8th People's Hospital
Sun Yat-sen University

Recruiting

The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function

HIV/AIDS

China
National Cancer Institute (NCI)

Enrolling by invitation

Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

Solid Tumors | Hematologic Malignancies | Pediatric Cancers

United States
Guangzhou Bio-gene Technology Co., Ltd

Active, not recruiting

A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma

T-Cell Acute Lymphocytic Leukemia

China
Affiliated Hospital to Academy of Military Medical...

Unknown

Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Kecellitics Biotech Company Ltd
Hebei Yanda Ludaopei Hospital

Unknown

Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL

Lymphoma | Leukemia
Shanghai Longyao Biotechnology Inc., Ltd.

Unknown

The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma | Relapsed and Refractory B Cell Lymphoma

China
Zhejiang University
Shanghai YaKe Biotechnology Ltd.

Recruiting

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Non-hodgkin Lymphoma,B Cell | Acute Lymphoblastic Leukemia,B-Cell

China
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

Clinical Study of Universal CAR-γδT Cell Injection in the Treatment of Patients With Relapsed AML After Transplantation

AML

China
RenJi Hospital

Unknown

CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR

Advanced Glioma

China
Nourhan M.Aly

Completed

Relapse and Failure Rates Between CAD/CAM and Conventional Fixed Retainers

Relapse

United States
University of Maryland, Baltimore

Completed

Group and Mobile Care for Gestational Diabetes

Gestational Diabetes

United States
He Huang
Yake Biotechnology Ltd.

Recruiting

A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma

Relapse/Refractory Multiple Myeloma

China
The University of Hong Kong

Recruiting

Combining Acupuncture and Acupressure for Dementia Elderly

Dementia

Hong Kong
Medical College of Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Follicular Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Central Nervous System Lymphoma | Mantle Cell Lymphoma (MCL) | Non Hodgkin Lymphoma (NHL)

United States
Beijing GoBroad Hospital

Not yet recruiting

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, in Relapse | Refractory Acute Lymphoblastic Leukemia | T-Cell Acute Lymphocytic Leukemia
Shenzhen Fifth People's Hospital

Recruiting

An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects

CAR T-Cell Therapy

China
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Unknown

CAR-T Re-treatment for Refractory/Relapsed Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Multiple Myeloma Progression

China
Akdeniz University

Completed

Orem's Self-Care Deficit Theory Based Nursing Interventions for Immunotherapy Treated Cancer Patients

Quality of Life | Cancer | Treatment Side Effects | Nurse's Role

Turkey
Ting Chang, MD

Not yet recruiting

Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

Myasthenia Gravis

China
RenJi Hospital

Completed

Anti-GPC3 CAR T for Treating Patients With Advanced HCC

Hepatocellular Carcinoma

China
Boston University

Enrolling by invitation

Ti-Mesh Frame Comparison for Alveolar Bone Augmentation

Tooth Loss

United States
Instituto de Investigación Biomédica de Salamanca
Carlos III Health Institute

Recruiting

Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment

Diffuse Large B Cell Lymphoma

Spain
Instituto de Investigación Biomédica de Salamanca
Spanish Clinical Research Network - SCReN; Fundación Canaria de Investigación... and other collaborators

Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19)

B-cell Lymphoma Recurrent | Refractory B-Cell Lymphoma

Spain
Zhu Xiaofan

Recruiting

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

B Lymphoblastic Lymphoma | B Lymphocytic Leukemia

China
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of Anti-CD1a CAR-T in the Treatment of R/R Acute T-lymphoblastic Leukemia/Lymphoblastic Lymphoma

Acute T-lymphoblastic Leukemia | Acute T-lymphoblastic Lymphoma

China
Centre Henri Becquerel

Not yet recruiting

Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells (RT-CAR)

Diffuse Large B Cell Lymphoma

France
Affiliated Hospital to Academy of Military Medical...
Beijing JD Biotech Co. LTD.

Recruiting

Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia Refractory | Acute Myeloid Leukemia Recurrent

China
Beijing Friendship Hospital
Beijing Boren Hospital

Not yet recruiting

Safety and Efficacy of CD207 Targeted CAR-T Cell Therapy in Patients With R/R Langerhans Cell Histiocytosis

Langerhans Cell Histiocytosis

China
Zhejiang University

Not yet recruiting

Evaluate the Safety and Efficacy of CLL1+CD33 CAR-T in Patients With R/R AML

AML

China
Ying Wang

Recruiting

CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies

Hematological Malignancies

China
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer

EGFR/ B7H3-positive Advanced Lung Cancer | EGFR/ B7H3-positive Advanced Triple-negative Breast Cancer

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies

AML

China
Zhejiang University
Yake Biotechnology Ltd.

Recruiting

Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies

AML

China

Search clinical trials for: car transportation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations